Literature DB >> 12064181

Alpha-2 adrenergic agonists as analgesics in horses.

David A Daunt1, Eugene P Steffey.   

Abstract

Administration of alpha-2 agonists to horses produces a variety of behavioral effects (sedation, somnolence, analgesia), and physiological effects. One of the most significant beneficial effects of administering alpha-2 agonists is the degree of analgesia they provide. Alpha-2 agonists have been the mainstay of analgesia for colic pain in horses since their introduction to clinical veterinary medicine. The increased potency of the more recently introduced alpha-2 agonists allows the provision of analgesia for conditions not previously relieved by other drugs. Unfortunately, there are significant side effects associated with alpha-2 agonist administration. Studies are underway to identify the physiologic effects associated with the stimulation of each alpha-2 receptor subtype, in hopes of developing subtype-specific alpha-2 agonists and antagonists.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12064181     DOI: 10.1016/s0749-0739(02)00004-4

Source DB:  PubMed          Journal:  Vet Clin North Am Equine Pract        ISSN: 0749-0739            Impact factor:   1.792


  3 in total

1.  Sedative and cardiopulmonary effects of buprenorphine and xylazine in horses.

Authors:  Fernando S F Cruz; Adriano B Carregaro; Melissa Machado; Rômulo R Antonow
Journal:  Can J Vet Res       Date:  2011-01       Impact factor: 1.310

2.  Evaluation of the effect of different sedative doses of dexmedetomidine on the intestinal motility in clinically healthy donkeys (Equus asinus).

Authors:  Marwa Abass; Hussam Ibrahim; Hakan Salci; Mohamed A Hamed
Journal:  BMC Vet Res       Date:  2022-07-14       Impact factor: 2.792

3.  Xylazine Activates Adenosine Monophosphate-Activated Protein Kinase Pathway in the Central Nervous System of Rats.

Authors:  Xing-Xing Shi; Bai-Shuang Yin; Peng Yang; Hao Chen; Xin Li; Li-Xue Su; Hong-Gang Fan; Hong-Bin Wang
Journal:  PLoS One       Date:  2016-04-06       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.